Clinical Trial Update: A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) [Phase 1]

View source ↗

Summary

Phase I dose-escalation study of GSK2879552 in subjects with acute myeloid leukemia was terminated early; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• GSK2879552

Snippet

Sponsor: GlaxoSmithKline | Conditions: Leukaemia, Myelocytic, Acute | Phase 1 | Status: TERMINATED | Results posted: 2019-06-28